Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > NanoViricides, Inc. to File Annual Report Shortly; Discusses Status of Current Projects

Abstract:
Temporary Stock Symbol Change Will Be Reversed

NanoViricides, Inc. to File Annual Report Shortly; Discusses Status of Current Projects

WEST HAVEN, CT | Posted on October 6th, 2008

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), commented on the recent and temporary change of its quotation symbol from NNVC.OB to NNVCE.OB. The "E" reflects that the Company has not yet filed its Form 10-KSB, annual report to shareholders. The Company's symbol will return to NNVC.OB once the Form 10-KSB is filed. The Company anticipates it will file our annual report within the time provided and expects there to be no significant change in its financial statements.

Commenting on this event, Eugene Seymour, MD, MPH, the Company's Chief Executive Officer, stated "We want to assure our stockholders that nothing about the Company has changed. We remain committed to both our mission and our science and we will rectify this issue within ten days."

"Following recently disclosed successful financing, we are now busy scheduling the follow-on studies against HIV as well as adenoviral EKC. We have received significant interest from several major pharmaceutical companies, as well as governmental and non-profit institutions for nanoviricides development against these diseases," he further added.

"We are now gathering significant and valuable input for these studies from important stakeholders interested in furthering development of highly effective drugs against these major diseases," said Anil R. Diwan, PhD, President of the Company.

The Company further reports that the next stage in the evaluation of anti-rabies nanoviricides is expected to begin soon at the Centers for Disease Control and Prevention in Atlanta, GA, under a previously announced signed Materials Cooperative Research and Development Agreement (M-CRADA). The anti-influenza projects, viz. FluCide™-I against common influenzas, and FluCide-HP™ against all highly pathogenic avian influenzas (bird flu, including H5N1, H7N and H9N), are awaiting certain animal studies protocol approvals. The Company is currently developing additional ligands against the Ebola virus, following successful initial in vitro studies, to overcome the potential problem of soluble surface glycoprotein shed by the virus in animal infection. The Company plans to report on additional projects undertaken as they proceed.

####

About NanoViricides, Inc.
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, EKC, hepatitis C, rabies, dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied including the success of the Company's research and development efforts, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process, described in the “Management’s Discussion and Analysis” section of the Company’s Form 10-KSB and other reports and filings with the Securities and Exchange Commission.

For more information, please click here

Contacts:
NanoViricides, Inc.
Amanda Schuon
310-550-7200

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

New Biological Nano-Fertilizers Presented in Iran as Appropriate Replacements for Chemical Fertilizers April 18th, 2015

Iranian Foodstuff, Agricultural Industries Welcome Nanotechnology Packaging Bags April 18th, 2015

Nanocomposites Play Effective Role in Production of Smart Fibers April 18th, 2015

Dais Analytic Corporation Appoints Eliza Wang to Board of Directors: Company's Newest Director Brings Expertise in Commercial and Legal Matters Both in the United States and China; Joins on the Heels of Successful Business Development Trade Mission to China April 18th, 2015

Investments/IPO's/Splits

Long Island Capital Alliance Announces Participants for Brookhaven National Laboratory Technology Transfer Capital Forum on May 8: Keynote Speaker Dr. Doon Gibbs, Director of Brookhaven National Laboratory April 16th, 2015

Graphenea embarks on a new era April 16th, 2015

Harris & Harris Group Portfolio Company OpGen Files Amended Registration Statement for Proposed Public Offering April 8th, 2015

Harris & Harris Group Reports Financial Statements as of December 31, 2014 and Posts Annual Letter to Shareholders on Website March 17th, 2015

Nanomedicine

Optical resonance-based biosensors designed for medical applications April 18th, 2015

Nanocomposites Play Effective Role in Production of Smart Fibers April 18th, 2015

Novel nanoparticles could save soldiers' lives after explosions April 15th, 2015

Nanoparticles at specific temperature stimulate antitumor response: Dartmouth researchers identify precise heat to boost immune system against cancer tumors April 14th, 2015

Announcements

New Biological Nano-Fertilizers Presented in Iran as Appropriate Replacements for Chemical Fertilizers April 18th, 2015

Iranian Foodstuff, Agricultural Industries Welcome Nanotechnology Packaging Bags April 18th, 2015

Nanocomposites Play Effective Role in Production of Smart Fibers April 18th, 2015

Dais Analytic Corporation Appoints Eliza Wang to Board of Directors: Company's Newest Director Brings Expertise in Commercial and Legal Matters Both in the United States and China; Joins on the Heels of Successful Business Development Trade Mission to China April 18th, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2015 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE